Účtovná hodnota akcie spoločnosti Genocea Biosciences Inc
Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Genocea Biosciences Inc?
Hodnota metriky Účtovná hodnota akcie spoločnosti Genocea Biosciences Inc je 0.00
Aká je definícia metriky Účtovná hodnota akcie?
Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Účtovná hodnota akcie spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Genocea Biosciences Inc
Čomu sa venuje spoločnosť Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Genocea Biosciences Inc
- Hodnota metriky Účtovná hodnota akcie spoločnosti Cycliq je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti B. Riley Principal Merger II je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti FG Acquisition je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Nexway AG je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti THC Therapeutics je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Thoma Bravo Advantage je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Genocea Biosciences Inc je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Canada Rare Earth je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Galilee je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti PT Aneka Tambang Tbk je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Coho Collective Kitchens je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti My Rewards International Ltd je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Six Sigma Metals je 0.00